Chardan Capital Maintains Buy on Taysha Gene Therapies, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and raises the price target from $5 to $7.
March 21, 2024 | 8:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on Taysha Gene Therapies and increases the price target from $5 to $7.
The upgrade in price target by a reputable analyst like Geulah Livshits signals a strong vote of confidence in Taysha Gene Therapies' future prospects. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100